Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trialSimeon Schietzel, Daniel G. Fuster, Grazia M. Cereghetti et al.|BMJ Open|2022Cited by 31
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trialManuel Anderegg, Daniel G. Fuster, Simeon Schietzel et al.|Nature Medicine|2025Cited by 25
Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formersMatthias B. Moor, Daniel G. Fuster, Nasser A. Dhayat et al.|Urolithiasis|2022Cited by 4
Severe hypomagnesemiaSimeon Schietzel, Daniel G. Fuster, Matthias B. Moor|Journal of Nephrology|2021Cited by 1